Finally, this NGS approach revealed gains of different regions including MUTYH, CDK4, KRAS, POLE, ERBB2, TP53, POLD1, and STK11 in both NEC and endometrioid tumors. Here, KRAS is linked to neuroendocrine carcinoma.